Genedrive PLC (GB:GDR)
LSE:GDR
GDR Stock Chart & Stats
0.88 p
0.03 p(1.30%)
At close: 4:00 PM EST
0.88 p
0.03 p(1.30%)
Day’s Range― - ―
52-Week Range0.19 p - 1.85 p
Previous CloseN/A
Volume280.42K
Average Volume (3M)49.58M
Market Cap
£15.25M
Enterprise Value4.39M
Total Cash (Recent Filing)£1.18M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-1.35
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform + Consumables Revenue ModelA combined instrument-plus-consumables model creates recurring revenue as tests are single-use. This structural mix supports predictable unit economics over time, enables margin expansion as volume scales, and aligns incentives with customer adoption in hospitals and near-patient settings.
Accelerating Revenue GrowthSustained top-line acceleration off a small base indicates improving commercial traction and market acceptance of the platform. If maintained, this trend can drive operating leverage, spread fixed costs, and materially improve margins and cash conversion over the next several quarters.
Low Leverage / Negligible DebtHaving no meaningful debt reduces interest and refinancing risk, giving the company structural financial flexibility. This lowers short-term solvency pressure and preserves capacity to raise equity or partner strategically to fund commercial roll-out without interest cost drag.
Bears Say
Persistent Negative ProfitabilitySustained negative EBIT and net losses mean the core business is not yet self-funding. Ongoing operating losses will require external capital or structural cost reduction to reach break-even, and prolonged deficits can erode competitive position and limit reinvestment capacity.
Material Cash BurnPersistent negative operating and free cash flow indicates the company consumes cash to fund growth and operations. This structural burn creates dependency on external financing, increases dilution risk, and constrains ability to scale sales, regulatory work, or assay development without new capital.
Compressed Equity Base And Funding RiskA shrunken equity base reduces the balance-sheet cushion against losses and limits capacity to absorb shocks. With a history of prior balance-sheet stress, this structural weakness raises the probability of future dilution or difficult funding rounds as the company seeks to sustain operations.
Genedrive News
GDR FAQ
What was Genedrive PLC’s price range in the past 12 months?
Genedrive PLC lowest share price was 0.19 p and its highest was 1.85 p in the past 12 months.
What is Genedrive PLC’s market cap?
Genedrive PLC’s market cap is £15.25M.
When is Genedrive PLC’s upcoming earnings report date?
Genedrive PLC’s upcoming earnings report date is Nov 26, 2026 which is in 235 days.
How were Genedrive PLC’s earnings last quarter?
Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Genedrive PLC overvalued?
According to Wall Street analysts Genedrive PLC’s price is currently Overvalued.
Does Genedrive PLC pay dividends?
Genedrive PLC does not currently pay dividends.
What is Genedrive PLC’s EPS estimate?
Genedrive PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genedrive PLC have?
Genedrive PLC has 1,605,568,200 shares outstanding.
What happened to Genedrive PLC’s price movement after its last earnings report?
Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Genedrive PLC?
Currently, no hedge funds are holding shares in GB:GDR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genedrive PLC
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Renalytix
―
Abingdon Health PLC
―
Aptamer Group Plc
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---